ClinicalTrials.gg
CompletedNCT01147666Updated Jan 11, 2022Results posted

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

A Phase 2 interventional study of Roxadustat and Epoetin Alfa in End Stage Renal Disease and Anemia, sponsored by FibroGen. Completed at 25 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by FibroGen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing roxadustat in Kidney Failure, Chronic — 2 open to participants now, 3 under way, 1 of them phase 3. roxadustat · Kidney Failure, Chronic.

Enrollment
8th of 15
161 · median 161
Started
2010
the only one that year
Phase 2
5 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
9 of 15
FibroGen

Among the 15 studies testing roxadustat in Kidney Failure, Chronic, this one is the 8th largest by enrollment, is the only one that started in 2010, is one of 5 in phase 2, and was the 1st registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

2 of the 15 studies testing roxadustat in Kidney Failure, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing roxadustat in Kidney Failure, Chronic, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of roxadustat in participants with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) therapy, previously treated with intravenous (IV) epoetin alfa.

Read the detailed description

Dose ranging study with consecutive cohorts in two participant populations: participants normally responding to current anemia treatment (epoetin alfa) ("normoresponders": participants with baseline epoetin alfa dose at study entry 75 to 450 international units [IU]/kilograms [kg]/week) and participants not responding well to current treatment ("hyporesponders": participants with maintenance epoetin alfa dose above 450 IU/kg/week). Normoresponders are randomized to study drug roxadustat or epoetin alfa at a ratio of 3:1; hyporesponders are randomized to study drug roxadustat or epoetin alfa or placebo at a ratio of 2:1:1. The study objectives are to demonstrate that roxadustat is effective in maintaining hemoglobin (Hb) levels when converting from epoetin alfa and to establish optimum starting doses and dose adjustment regimens for Hb maintenance.

03

Conditions studied

  • End Stage Renal Disease
  • Anemia

Keywords

  • Kidney
  • End Stage Renal Disease
  • ESRD
  • Chronic Kidney Disease
  • CKD
  • Renal
  • Anemia
  • Oral anemia treatment
  • Hemoglobin levels
  • Blood count
  • Erythropoietin
  • Hemodialysis
  • Normoresponder
  • Hyporesponder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • ESRD and receiving maintenance HD TIW for ≥4 months prior to Day 1
  • Two most recent values obtained during screening period must be within the ranges set below:

    i) Group A. Normoresponder Criteria: Hb range in the 8 weeks prior to randomization within 9.0 to 13.5 g/dL ii) Group B. Hyporesponder Criteria: Hb range in the 8 weeks prior to randomization within 8.5 to 13.5 g/dL

  • Epoetin alfa, dose requirements:

    i) Group A. Normoresponder Criteria - Cohorts A-1 to A-12: Stable IV epoetin alfa dose at baseline (that is, no more than a 30% fluctuation in the weekly dose) during the 4 weeks prior to study Day -3

    1. Cohorts A-1 to A-4: Current and previous (past 4 weeks) epoetin alfa dose range 25 to 85 IU/kg/dose, TIW; weekly dose between 75 and 255 IU/kg/week
    2. Cohort A-5: Current and previous (past 4 weeks) epoetin alfa dose range ≥85 to 115 IU/kg/dose, TIW; total weekly dose between 255 and 450 IU/kg/week
    3. Cohort A-9: Current and previous (past 4 weeks) epoetin alfa dose range ≥85 to 150 IU/kg/dose, TIW; total weekly dose between 255 and 450 IU/kg/week
    4. Cohorts A-6 to A-8: Current and previous (past 4 weeks) epoetin alfa dose range 25 to 115 IU/kg/dose, TIW, and two times a week (BIW); total weekly dose between 75 and 345 IU/kg/week
    5. Cohorts A-10 to A-12: Optional cohorts to be decided (TBD), dosing frequency and dose range to be determined by sponsor ii) Group B. Hyporesponder Criteria:

    <!-- -->

    1. Cohort B-1 (completed): Current and previous (past 4 weeks) epoetin alfa dose range 125 to 400 IU/kg/dose, TIW; weekly dose between 375 and 1200 IU/kg/week
    2. Cohort B-2 to B-4: Current and previous (past 4 weeks) epoetin alfa dose range >115 IU/kg/dose, TIW; total weekly dose >345 IU/kg/week no requirement for stability of epoetin alfa doses
  • Complete Blood Count (CBC), Hematology, liver function blood tests, serum folate and vitamin B12 within acceptable limits
  • Absence of active or chronic gastrointestinal bleeding
  • High sensitivity C-reactive protein (hsCRP) \<60 mg/liter for normoresponders Cohorts A-8 through A-12 enrolled under Amendment 3; no hsCRP criteria for hyporesponders
  • Body weight: 40 to 140 kg (dry weight)
  • (BMI): 18 to 45 kg/meter square (m\^2)
  • Dialysis vascular access via native arteriovenous fistula or synthetic graft, or permanent (tunneled) catheter (not via temporary catheter); permanent and temporary catheters, however, are still prohibited in Cohort A-5

Key Exclusion Criteria:

  • Anticipated change in HD prescription
  • Any infection or evidence of an underlying infection
  • Positive for any of the following: (HIV); surface antigen (HBsAg); or anti- virus antibody (anti-HCV Ab)
  • History of chronic liver disease
  • Class III or IV congestive heart failure
  • Chronic inflammatory disease that could impact erythropoiesis (for example, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
  • History of myelodysplastic syndrome
  • History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric
  • Active hemolysis or diagnosis of hemolytic syndrome
  • Known bone marrow fibrosis
  • Uncontrolled or symptomatic secondary hyperparathyroidism
  • Any prior organ transplantation
  • Drug-treated gastroparesis or short-bowel syndrome
  • History of alcohol or drug abuse; or a positive drug screen for a substance that has not been prescribed for the participant
  • Prior treatment with roxadustat
  • Diagnosis or suspicion of renal cell carcinoma
  • Red blood cell (RBC) transfusion within 12 weeks prior to Day 1, or anticipated need for RBC transfusion during the dosing period
  • IV iron supplement within 2 weeks prior to Day 1 and/or unwilling to withhold IV iron during the dosing/treatment period
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Cohort A-1 (Roxadustat 1.0 mg/kg TIW)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.0 milligrams (mg)/kg, administered orally 3 times weekly (TIW) in the morning of the day after dialysis (interdialytic days) for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 grams \[g\]/deciliter \[dL\]) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-2 (Roxadustat 1.5 mg/kg TIW)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-3 (Roxadustat 2.0 mg/kg TIW)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-4 (Roxadustat 1.8 mg/kg TIW)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-5 (Roxadustat 1.8 mg/kg TIW)

    Normoresponsive participants (with baseline epoetin alfa dosage 85-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-6 (Roxadustat 1.3 mg/kg TIW)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.3 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.3 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 100 mg, and 150 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-9 (Roxadustat 2.0 mg/kg)

    Normoresponsive participants (with baseline epoetin alfa dosage 85-150 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)

    Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Active comparator
    Cohorts A (Epoetin Alfa)

    Normoresponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort A. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.

    Drug: Epoetin Alfa

  • Experimental
    Cohort B-1 (Roxadustat 1.5 mg/kg TIW)

    Hyporesponsive participants (with baseline epoetin alfa dosage 125-400 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Experimental
    Cohort B-2 (Roxadustat 2.0 mg/kg TIW)

    Hyporesponsive participants (with baseline epoetin alfa dosage \>115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.

    Drug: Roxadustat

  • Active comparator
    Cohort B (Epoetin Alfa)

    Hyporesponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort B. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.

    Drug: Epoetin Alfa

  • Placebo comparator
    Cohort B (Placebo)

    Hyporesponsive participants will receive placebo matched to roxadustat, administered orally TIW for 19 weeks.

    Other: Placebo

Interventions

  • Roxadustat will be administered per dose and schedule specified in the arms.

    Also known as: FG-4592

  • Epoetin Alfa will be administered per dose and schedule specified in the arms.

  • OtherPlacebo

    Placebo matching to roxadustat will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only

    Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. Last observation carried forward (LOCF) method was used to impute missing values.

    Time frame: Week 7

  2. Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks

    Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.

    Time frame: Week 7

  3. Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks

    The average of the mean Hb values that were above 11 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.

    Time frame: Weeks 17, 18, 19, and 20

Secondary outcomes

  1. Number of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)

    The average of the mean Hb values that were within 11-13 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.

    Time frame: Weeks 17, 18, 19, and 20

  2. Number of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)

    The average of the mean Hb values that were within 10-13 g/dL at Weeks 17, 18, 19, and 20 are presented. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants. LOCF method was used to impute missing values.

    Time frame: Weeks 17, 18, 19, and 20

  3. Change From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks

    Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.

    Time frame: Baseline, Week 7

  4. Change From Baseline in Hb at Weeks 8, 10, 12, 14, 17, 19, and 20 for Participants Treated for 7-19 Weeks

    Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.

    Time frame: Baseline, Weeks 8, 10, 12, 14, 17, 19, and 20

  5. Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 6 Weeks Only

    Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

    Time frame: Baseline up to Week 6

  6. Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 19 Weeks

    Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

    Time frame: Baseline up to Week 19

  7. Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks

    Time frame: Week 7

  8. Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks

    Time frame: Week 7

  9. Number of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level

    Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

    Time frame: Week 7

  10. Number of Participants Treated for 7-19 Weeks Whose Hb Levels at Weeks 8, 10, 12, 14, 17, 19, and 20 Were Greater Than Their Baseline Level

    Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

    Time frame: Weeks 8, 10, 12, 14, 17, 19, and 20

  11. Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks

    Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.

    Time frame: Baseline up to Week 6

  12. Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks

    Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.

    Time frame: Baseline up to Week 19

  13. Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks

    Time frame: Baseline up to Week 6

  14. Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks

    Time frame: Baseline up to Week 19

  15. Rate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6

    The rate of rise was computed as the slope of the regression line of change in Hb level (in g/dL) vs. time (in weeks) using Random Coefficient Model. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

    Time frame: Baseline up to Week 6

  16. Trough Plasma Concentration of Roxadustat and Epoetin Alfa

    Time frame: Predose, 4, 8, 12, 24, 48, and 72 hours postdose at Weeks 1 and 6

07

Results

Posted Jan 11, 2022

Participant flow

Dosing Period 1: 6-Week Treatment
Participant flow — Dosing Period 1: 6-Week Treatment
MilestoneCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Started1212121212121212210364544
Received at least 1 dose of study drug1212121212121212210364544
Efficacy evaluable (ee) population91091111111110210311343
Completed10101110799928332130
Not completed221253330232414
Withdrew: Adverse event111000000000100
Withdrew: Lack of efficacy010031220100103
Withdrew: Death000011100000100
Withdrew: Protocol violation100100000010000
Withdrew: Withdrawal by subject000011010101010
Withdrew: Other than specified000100000020000
Withdrew: Non-compliance with study drug000000000001101
Dosing Period 2: 19-Week Treatment
Participant flow — Dosing Period 2: 19-Week Treatment
MilestoneCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Started000712121212210230533
Received at least 1 dose of study drug000712121212210230533
Ee population for 19-week treatment000611111110210220332
Completed0005799928210120
Not completed000253330220413
Withdrew: Death000011100000100
Withdrew: Lack of efficacy000031220100102
Withdrew: Protocol violation000100000000000
Withdrew: Withdrawal by subject000011010100010
Withdrew: Other than specified000100000020000
Withdrew: Adverse event000000000000100
Withdrew: Non-compliance with study drug000000000000101

Outcome measures

PrimaryNumber of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only

Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. Last observation carried forward (LOCF) method was used to impute missing values.

Time frame:
Week 7
Reported as:
Count of participants · Participants
Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only
ParticipantsCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A (Epoetin Alfa)
Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only48743
Statistical analysis
  • Cohort A-1 (Roxadustat 1.0 mg/kg TIW) vs Cohort A (Epoetin Alfa) · Fisher Exact · p = 1.0000 (Threshold for significance at 0.05 level.)
  • Cohort A-2 (Roxadustat 1.5 mg/kg TIW) vs Cohort A (Epoetin Alfa) · Fisher Exact · p = 0.0698 (Threshold for significance at 0.05 level.)
  • Cohort A-3 (Roxadustat 2.0 mg/kg TIW) vs Cohort A (Epoetin Alfa) · Fisher Exact · p = 0.1534 (Threshold for significance at 0.05 level.)
  • Cohort A-4 (Roxadustat 1.8 mg/kg TIW) vs Cohort A (Epoetin Alfa) · Fisher Exact · p = 0.2657 (Threshold for significance at 0.05 level.)
PrimaryNumber of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks

Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.

Time frame:
Week 7
Reported as:
Count of participants · Participants
Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks
ParticipantsCohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks0120
Statistical analysis
  • Cohort B-2 (Roxadustat 2.0 mg/kg TIW) vs Cohort B (Placebo) · Fisher Exact · p = 1.0000 (Threshold for significance at 0.05 level.)
PrimaryNumber of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks

The average of the mean Hb values that were above 11 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.

Time frame:
Weeks 17, 18, 19, and 20
Reported as:
Count of participants · Participants
Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks44656248000
SecondaryNumber of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)

The average of the mean Hb values that were within 11-13 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.

Time frame:
Weeks 17, 18, 19, and 20
Reported as:
Count of participants · Participants
Number of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)41656238000
SecondaryNumber of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)

The average of the mean Hb values that were within 10-13 g/dL at Weeks 17, 18, 19, and 20 are presented. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants. LOCF method was used to impute missing values.

Time frame:
Weeks 17, 18, 19, and 20
Reported as:
Count of participants · Participants
Number of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)
Number of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)52101072619
SecondaryChange From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks

Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.

Time frame:
Baseline, Week 7
Reported as:
Mean · g/dL
Change From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks
g/dLCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Change From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks-0.40 ± 1.560.91 ± 1.590.71 ± 1.610.25 ± 1.86-0.15 ± 1.36-0.18 ± 1.55-0.32 ± 1.39-0.47 ± 0.94-0.00 ± 2.120.24 ± 1.82-0.51 ± 1.31-2.63-0.89 ± 0.74-0.28 ± 0.81-2.50 ± 0.23
SecondaryChange From Baseline in Hb at Weeks 8, 10, 12, 14, 17, 19, and 20 for Participants Treated for 7-19 Weeks

Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.

Time frame:
Baseline, Weeks 8, 10, 12, 14, 17, 19, and 20
Reported as:
Mean · g/dL
Change From Baseline in Hb at Weeks 8, 10, 12, 14, 17, 19, and 20 for Participants Treated for 7-19 Weeks
g/dLCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Change at Week 80.49 ± 1.310.08 ± 1.560.01 ± 1.51-0.49 ± 1.49-0.29 ± 1.090.05 ± 2.050.20 ± 1.85-0.21 ± 1.02-0.89 ± 0.99-0.41 ± 1.52-2.37 ± 0.00
Change at Week 100.56 ± 1.490.17 ± 1.65-0.17 ± 1.32-0.56 ± 1.35-0.27 ± 1.22-0.15 ± 0.070.26 ± 2.07-0.34 ± 1.19-1.46 ± 1.410.19 ± 1.48-2.37 ± 0.00
Change at Week 120.26 ± 1.490.04 ± 1.57-0.10 ± 1.42-0.56 ± 1.44-0.35 ± 1.17-0.15 ± 0.920.38 ± 2.28-0.48 ± 1.20-2.02 ± 1.47-0.08 ± 2.50-2.37 ± 0.00
Change at Week 140.53 ± 1.55-0.03 ± 1.73-0.27 ± 1.29-0.41 ± 1.44-0.24 ± 1.68-0.15 ± 1.770.33 ± 2.37-0.50 ± 1.23-2.29 ± 1.710.42 ± 1.83-2.37 ± 0.00
Change at Week 17-0.09 ± 0.88-0.09 ± 1.96-0.27 ± 1.07-0.48 ± 1.42-0.27 ± 1.18-0.30 ± 0.850.02 ± 2.06-0.45 ± 1.57-2.69 ± 1.610.16 ± 2.27-2.37 ± 0.00
Change at Week 19-0.11 ± 1.18-0.32 ± 1.84-0.28 ± 1.07-0.82 ± 1.19-0.35 ± 1.200.05 ± 0.07-0.10 ± 2.03-0.30 ± 1.43-3.02 ± 1.080.12 ± 2.27-2.37 ± 0.00
Change at Week 20-0.39 ± 1.16-0.55 ± 1.88-0.55 ± 1.24-0.82 ± 1.27-0.33 ± 1.340.15 ± 0.07-0.57 ± 1.68-0.36 ± 1.50-2.82 ± 1.190.12 ± 2.14-2.47 ± 0.14
SecondaryNumber of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 6 Weeks Only

Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

Time frame:
Baseline up to Week 6
Reported as:
Count of participants · Participants
Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 6 Weeks Only
ParticipantsCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A (Epoetin Alfa)
Dose Increased03009
Dose Reduced00026
Dose Interrupted47403
Dose Resume06400
SecondaryNumber of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 19 Weeks

Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

Time frame:
Baseline up to Week 19
Reported as:
Count of participants · Participants
Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 19 Weeks
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)
Dose Increased255471812
Dose Reduced335441611
Dose Interrupted15201039
Dose Resume03101018
SecondaryNumber of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks
Time frame:
Week 7
Reported as:
Count of participants · Participants
Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks
ParticipantsCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks3355436601190230
SecondaryNumber of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks
Time frame:
Week 7
Reported as:
Count of participants · Participants
Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks343660113230
SecondaryNumber of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level

Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

Time frame:
Week 7
Reported as:
Count of participants · Participants
Number of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level
ParticipantsCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A (Epoetin Alfa)
Number of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level37632
SecondaryNumber of Participants Treated for 7-19 Weeks Whose Hb Levels at Weeks 8, 10, 12, 14, 17, 19, and 20 Were Greater Than Their Baseline Level

Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

Time frame:
Weeks 8, 10, 12, 14, 17, 19, and 20
Reported as:
Count of participants · Participants
Number of Participants Treated for 7-19 Weeks Whose Hb Levels at Weeks 8, 10, 12, 14, 17, 19, and 20 Were Greater Than Their Baseline Level
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)
Week 836444169
Week 1036445067
Week 1236643159
Week 1436641166
Week 1725544166
Week 1924524168
Week 2033525257
SecondaryNumber of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks

Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.

Time frame:
Baseline up to Week 6
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks
ParticipantsCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks223423230461301
SecondaryNumber of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks

Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.

Time frame:
Baseline up to Week 19
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks42323044301
SecondaryNumber of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks
Time frame:
Baseline up to Week 6
Reported as:
Count of participants · Participants
Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks
ParticipantsCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks000102121460010
SecondaryNumber of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks
Time frame:
Baseline up to Week 19
Reported as:
Count of participants · Participants
Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks
ParticipantsCohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks00212146010
SecondaryRate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6

The rate of rise was computed as the slope of the regression line of change in Hb level (in g/dL) vs. time (in weeks) using Random Coefficient Model. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.

Time frame:
Baseline up to Week 6
Reported as:
Number · g/dL/week
Rate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6
g/dL/weekCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A (Epoetin Alfa)
Rate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6-0.01350.19260.1682-0.0220-0.1267
SecondaryTrough Plasma Concentration of Roxadustat and Epoetin Alfa
Time frame:
Predose, 4, 8, 12, 24, 48, and 72 hours postdose at Weeks 1 and 6

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to Week 23. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A-1 (Roxadustat 1.0 mg/kg TIW)—0/12 (0%)3/12 (25%)
Cohort A-2 (Roxadustat 1.5 mg/kg TIW)—3/12 (25%)1/12 (8.3%)
Cohort A-3 (Roxadustat 2.0 mg/kg TIW)—0/12 (0%)1/12 (8.3%)
Cohort A-4 (Roxadustat 1.8 mg/kg TIW)—4/12 (33.3%)4/12 (33.3%)
Cohort A-5 (Roxadustat 1.8 mg/kg TIW)—5/12 (41.7%)2/12 (16.7%)
Cohort A-6 (Roxadustat 1.3 mg/kg TIW)—3/12 (25%)2/12 (16.7%)
Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)—5/12 (41.7%)1/12 (8.3%)
Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)—3/12 (25%)2/12 (16.7%)
Cohort A-9 (Roxadustat 2.0 mg/kg)—0/2 (0%)0/2 (0%)
Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)—3/10 (30%)3/10 (30%)
Cohorts A (Epoetin Alfa)—6/36 (16.7%)2/36 (5.6%)
Cohort B-1 (Roxadustat 1.5 mg/kg TIW)—2/4 (50%)3/4 (75%)
Cohort B-2 (Roxadustat 2.0 mg/kg TIW)—2/5 (40%)2/5 (40%)
Cohort B (Epoetin Alfa)—1/4 (25%)0/4 (0%)
Cohort B (Placebo)—0/4 (0%)1/4 (25%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
CellulitisInfections and infestations0/121/120/120/120/120/120/120/120/20/100/361/40/50/40/4
Diverticular perforationGastrointestinal disorders0/120/120/120/120/120/120/120/120/20/100/360/40/51/40/4
Retroperitoneal haemorrhageGastrointestinal disorders0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
Vascular pseudoaneurysm rupturedInjury, poisoning and procedural complications0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
Non-cardiac chest painGeneral disorders0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
BacteraemiaInfections and infestations0/120/120/120/120/120/120/120/120/20/100/360/41/50/40/4
Cardiac failure congestiveCardiac disorders0/120/120/120/120/120/121/120/120/20/101/360/41/50/40/4
Haemorrhagic strokeNervous system disorders0/120/120/120/120/120/120/120/120/20/100/360/41/50/40/4
Acute myocardial infarctionCardiac disorders0/122/120/120/120/120/120/120/120/20/100/360/40/50/40/4
HypocalcaemiaMetabolism and nutrition disorders0/120/120/120/120/120/120/120/120/21/100/360/40/50/40/4
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)
NauseaGastrointestinal disorders3/120/121/121/120/120/120/122/120/21/100/360/41/50/40/4
Arteriovenous fistula site complicationInjury, poisoning and procedural complications0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
HeadacheNervous system disorders0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
SyncopeNervous system disorders0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
AnaemiaBlood and lymphatic system disorders0/120/120/122/120/120/121/120/120/22/100/361/40/50/41/4
Catheter site painGeneral disorders0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
Ingrowing nailSkin and subcutaneous tissue disorders0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
Post procedural swellingInjury, poisoning and procedural complications0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
CellulitisInfections and infestations0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4
Otitis ExternaInfections and infestations0/120/120/120/120/120/120/120/120/20/100/361/40/50/40/4

Baseline characteristics

Safety population included all participants who were randomized and received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Cohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)Total
Mean55.1 ± 12.158.8 ± 13.656.6 ± 10.850.8 ± 19.455.2 ± 10.658.7 ± 10.161.9 ± 11.955.7 ± 14.557.0 ± 17.055.8 ± 6.857.9 ± 11.055.0 ± 8.860.2 ± 5.947.0 ± 12.558.8 ± 8.656.3 ± 3.680644
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A-1 (Roxadustat 1.0 mg/kg TIW)Cohort A-2 (Roxadustat 1.5 mg/kg TIW)Cohort A-3 (Roxadustat 2.0 mg/kg TIW)Cohort A-4 (Roxadustat 1.8 mg/kg TIW)Cohort A-5 (Roxadustat 1.8 mg/kg TIW)Cohort A-6 (Roxadustat 1.3 mg/kg TIW)Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)Cohort A-9 (Roxadustat 2.0 mg/kg)Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)Cohorts A (Epoetin Alfa)Cohort B-1 (Roxadustat 1.5 mg/kg TIW)Cohort B-2 (Roxadustat 2.0 mg/kg TIW)Cohort B (Epoetin Alfa)Cohort B (Placebo)Total
Female417542541313352261
Male811578107817231022100
08

Study locations

25 sites
  • Tempe, Arizona, United States
  • Pine Bluff, Arkansas, United States
  • Azusa, California, United States
  • Los Angeles, California, United States
  • Northridge, California, United States
  • Ontario, California, United States
  • Paramount, California, United States
  • Yuba City, California, United States
  • Miami, Florida, United States
  • Pembroke Pines, Florida, United States
  • Honolulu, Hawaii, United States
  • Louisville, Kentucky, United States
  • Detroit, Michigan, United States
  • Kansas City, Missouri, United States
  • Paterson, New Jersey, United States
  • New York, New York, United States
  • Rosedale, New York, United States
  • Williamsville, New York, United States
  • Toledo, Ohio, United States
  • Orangeburg, South Carolina, United States
  • Arlington, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Fairfax, Virginia, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Oct 2012, 28 months.

Results were first posted in Jan 2022, 9 years 2 months after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 28 months is above that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
Jun 22, 2010
StartActual
May 17, 2010
Primary completionActual
Oct 15, 2012
CompletionActual
Oct 15, 2012
Results first posted
Jan 11, 2022
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01147666
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
May 17, 2010
Primary completion
Oct 15, 2012
Completion
Oct 15, 2012
Results posted
Jan 11, 2022
Last update
Jan 11, 2022

Study contacts

Marietta Franco
study director · FibroGen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion